Clinical Trial to Evaluate Safety and Efficacy of Jalosome® Soothing Gel.

Radiation-induced Dermatitis Clinical Trial

— JALOSOME-01  

Official title:

Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate Safety and Efficacy of Jalosome® Soothing Gel in the Prevention and Treatment of Radiation-induced Dermatitis in Patients With Head and Neck Cancer.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05284487
• Other study ID #: JALOSOME-01
• Status: Recruiting
• Phase: N/A
• Start date: March 27, 2023
• Est. completion date: March 2024

Study information

• Verified date: March 2023
• Source: Welcare Industries SpA
• Contact: Marco Gobbino
• Phone: +39 (0)763 316353
• Email: r&s[@]welcaremedical.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Primary objective

• To investigate the effectiveness of Jalosome® compared with placebo in the prevention and treatment of RID in patients with HNC undergoing RT.

Secondary objectives:

• To investigate the effectiveness of Jalosome® in reducing the maximum severity of RID compared with placebo.

• To investigate the effect of Jalosome®, compared with placebo, on patients' quality of life.

• To investigate safety and tolerability of Jalosome®.

• To investigate patient's compliance to Jalosome® treatment.

• To investigate patient's global satisfaction with Jalosome® treatment.

Description:

Primary endpoint:

• Mean time difference in development of G2 RID (according to CTCA) between Jalosome® and placebo arms. A median difference of at least 7 days is considered of clinical significance.

• Secondary endpoints:

• Proportion of subjects without G2 RID at the end of RT, in the Jalosome® and placebo arms.

• Proportion of subjects without G2 RID at different timepoints (week 5, week 6 and two weeks after the last radiation) in the Jalosome® and placebo arms.

• Worst skin toxicity during treatment and up to 2 weeks after the last radiation, according to CTCAE, in the Jalosome® and placebo arms.

• RID grade (mean and worst) on the RISRAS scale, assessed weekly, in the Jalosome® and placebo arms.

• Mean and worst score of PRO-Skindex-16 questionnaire performed weekly, in the Jalosome® and placebo arms.

• Mean pain measured by the 11-point NRS of the Brief Pain Inventory (BPI), as reported in patients' diary (daily) and assessed during visits (weekly), in the Jalosome® and placebo arms.

• Patient's compliance to Jalosome® treatment.

• Patient's global satisfaction with Jalosome® treatment.

• Jalosome® overall safety and tolerability.

Study design:

Monocentric, randomized, double-blind, placebo controlled clinical trial.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 57
• Est. completion date: March 2024
• Est. primary completion date: February 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male and female subject aged =18 years old.

• Performance status 0-1.

• Diagnosis of HNC (epithelial carcinoma of oropharynx, nasopharynx, larynx, hypopharynx, paranasal sinuses or salivary glands).

• Postoperative or curative RT (total radiation dose of at least 60 Gy), with or without concurrent chemotherapy.

• Willingness and ability to give informed consent and comply with study procedures.

Exclusion Criteria:

• Pregnant or lactating women.

• Previous RT on the head and neck area.

• Planned to receive concurrent cetuximab.

• Cutaneous and/or connective diseases (i.e. lupus erythematosus or scleroderma).

• Systemic diseases known to delay the skin healing process, such as diabetes mellitus or severe renal failure.

• Use of a tissue-equivalent bolus.

• Use of over-the-counter topical medications containing steroids.

• Presence of rashes or unhealed wounds in the radiation field.

• Recent sun exposure (<1 month).

• Mental conditions that could adversely affect subject's adherence to the study.

Related Conditions & MeSH terms

• Dermatitis
• Radiation-induced Dermatitis
• Radiodermatitis

Intervention

Device:
• Jalosome® soothing gel
Jalosome® Soothing gel is a phospholipid based vesicular system based on hyaluronic acid (HA). HA supports the process of formation of extracellular matrix and collagen synthesis by fibroblasts, favoring the formation of a well-vascularized granulation tissue and thus accelerating the healing process. Jalosome® Soothing gel contains other active ingredients: Acetyl-L-carnitine which plays an important role as shuttle for energy production and is involved in cellular metabolism. It is an effective cytoprotective, anti-inflammatory, neuroprotective, metal chelator, anti-apoptotic and anti-oxidant agent. Allantoin is a key constituent of comfrey (Symphytum officinale L), it has moisturizing and keratolytic effect, increasing the water content of the extracellular matrix and enhancing desquamation of upper layers of dead skin cells. Hydrogenated phosphatidylcholine is a permeation enhancers, which increases the solubilization of active ingredients, improving their skin permeation ability.
• Placebo
The placebo does not contain the active ingredients of Jalosome, only the co-formulants.

Locations

Country	Name	City	State
Italy	IRCCS	Milan

Sponsors (1)

Lead Sponsor	Collaborator
Welcare Industries SpA

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to development of G2 RID	Mean number of days in development of G2 RID (according to CTCA), in the Jalosome® and placebo arms.	9 weeks
Secondary	Subjects without G2 RID at the end of RT	Number and percentage of subjects without G2 RID at the end of RT, in the Jalosome® and placebo arms..	9 weeks
Secondary	Subjects without G2 RID at different timepoints	Number and percentage of subjects without G2 RID at different timepoints (week 5, week 6 and two weeks after the last radiation) in the Jalosome® and placebo arms.	9 weeks
Secondary	Worst skin toxicity	Number and percentage of subjects with worst skin toxicity G3, G2 and G1 RID according to CTCAE v.4.0, during treatment and up to 2 weeks after the last administration of RT, in the Jalosome® and placebo arms.	9 weeks
Secondary	RID grade on the RISRAS	Mean RID grade on the Radiation-Induced Skin Reaction Assessment Scale scale (RISRAS), assessed weekly, in the Jalosome® and placebo arms.; RISRAS score varies from 0 to 36, where 0 is normal skin/no symptoms at all and 36 is the worst conditions in terms of erythema-Dry desquamation - Moist desquamation - necrosis of derma (14 points) and very severe symptoms (12 points).	9 weeks
Secondary	PRO-Skindex-16 questionnaire score	Mean score of each item (16 items) of PRO-Skindex-16 questionnaire performed weekly, in the Jalosome® and placebo arms. Each item is about skin discomfort, ancd the scores vary from 0 (no discomfort) to 6 (full discomfort).	9 weeks
Secondary	Pain measured by NRS	Mean pain measured by the 11-point Numeric rating scale (NRS) of the Brief Pain Inventory (BPI), as reported in patients' diary (daily) and assessed during visits (weekly), in the Jalosome® and placebo arms.; NRS score varies from 0 to 10, where 0 is no pain and 10 is the worst pain imaginable.	9 weeks
Secondary	Compliance	Number and percentage of patients with compliance to Jalosome® treatment =80%.	9 weeks
Secondary	Adverse events	Number and percentage of adverse events by grade, according to the CTCAE v.4.0, and relationship with the treatment.	9 weeks